September 2004

The alterations are the result of an agency review of findings from a clinical trial, and data from required postmarket studies.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The company first announced its intention to build the state-of-the-art facility as part of a €900 million investment in July 2024.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Xiao-Yan Cai, PhD, shares insights into her leadership style, the importance of motivation in the workplace, and how she balances repetition with innovation, discussing how hobbies and resilience uniquely shape her professional approach, emphasizing the value of perseverance and preparation in both science and life.

CHMP gave its opinion and a recommendation for marketing authorization to Fabhalta (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway.